DENALI THERAPEUTICS INC (DNLI) Stock Analyst Earnings Estimates
NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 48.7M -85.49% | 108.5M 122.79% | 330.531M 204.64% | 8.874M -100.00% | 23.016M | 97.436M 323.34% | 251.55M 158.17% | 486.24M 93.30% | 681.96M 40.25% | 960.25M 40.81% | 1.478B 53.92% | 1.74B 17.73% | |
| EBITDA YoY % growth | -287.2M -503.37% | -330.3M -15.01% | -179.973M 45.51% | -519.145M -173.87% | -538.718M -9.30% | -504.896M 6.28% | -436.179M 13.61% | -203.93M 53.25% | 156.58M 176.78% | 958.52M 512.16% | 1.434B 49.61% | 1.545B 7.74% | |
| EBIT YoY % growth | -295.8M -571.77% | -340.7M -15.18% | -196.699M 42.27% | -518.173M -155.15% | -570.571M -13.69% | -530.618M 7.00% | -485.039M 8.59% | -248.453M 48.78% | -41.286M 83.38% | 248.57M 702.07% | 789.37M 217.56% | 997.46M 26.36% | |
| Operating Margin | -607.39% | -314.01% | -59.51% | -5,839.23% | -2,479.02% | -544.58% | -192.82% | -51.10% | -6.05% | 25.89% | 53.41% | 57.33% | |
| EPS YoY % growth | -2.39 -1,019.23% | -2.60 -8.79% | -1.08 58.46% | -2.78 -147.22% | -3.08 -15.44% | -2.93 4.96% | -2.47 15.76% | -1.05 57.39% | -0.36 65.66% | 0.40 209.60% | 1.64 314.10% | 2.37 44.81% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 -21.65% | -0.77 -15.11% | -0.83 -6.58% | -0.80 -10.50% | -0.79 -2.48% | -0.78 -0.51% |
| Revenue Q2Q % growth | 4.383M | 10.635M | 6.038M | 7.65M | 11.924M 172.05% | 16.249M 52.79% |
| EBITDA Q2Q % growth | -124.692M -6.74% | -126.225M -4.44% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -140.352M -13.93% | -140.734M -8.39% | -157.546M -19.52% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.72 -22.03% | -0.73 | 0.01 | 1.88% |
| Q1 2025 Q2Q % growth | -0.78 | -0.70 | -0.08 | -11.43% |
| Q4 2024 Q2Q % growth | -0.67 22.09% | -0.82 | 0.15 | 18.24% |
| Q3 2024 Q2Q % growth | -0.63 12.50% | -0.63 | 0.00 | -0.50% |
| Q2 2024 Q2Q % growth | -0.59 -145.38% | -0.70 | 0.11 | 15.61% |
| Q1 2024 Q2Q % growth | -0.78 2.50% | -0.72 | -0.06 | -8.80% |
| Q4 2023 Q2Q % growth | -0.86 -14.67% | -0.82 | -0.04 | -4.84% |
| Q3 2023 Q2Q % growth | -0.72 14.29% | -0.82 | 0.10 | 12.04% |
| Q2 2023 Q2Q % growth | 1.30 370.83% | -0.70 | 2.00 | 286.35% |
| Q1 2023 Q2Q % growth | -0.80 -50.94% | -0.72 | -0.08 | -11.37% |
| Q4 2022 Q2Q % growth | -0.75 -20.97% | -0.81 | 0.06 | 6.94% |
| Q3 2022 Q2Q % growth | -0.84 -21.74% | -0.82 | -0.02 | -2.15% |
| Q2 2022 Q2Q % growth | -0.48 4.00% | -0.56 | 0.08 | 14.30% |
| Q1 2022 Q2Q % growth | -0.53 8.62% | -0.52 | -0.01 | -2.25% |
| Q4 2021 Q2Q % growth | -0.62 -132.46% | -0.42 | -0.20 | -46.88% |
| Q3 2021 Q2Q % growth | -0.69 -27.78% | -0.48 | -0.21 | -42.76% |
| Q2 2021 Q2Q % growth | -0.50 10.71% | -0.42 | -0.08 | -19.83% |
| Q1 2021 Q2Q % growth | -0.58 -5.45% | -0.35 | -0.23 | -65.09% |
| Q4 2020 Q2Q % growth | 1.91 441.07% | 0.01 | 1.90 | 23,968.75% |
| Q3 2020 Q2Q % growth | -0.54 -12.50% | 2.64 | -3.18 | -120.47% |
| Q2 2020 Q2Q % growth | -0.56 8.20% | -0.61 | 0.05 | 8.65% |
| Q1 2020 Q2Q % growth | -0.55 -34.15% | -0.58 | 0.03 | 5.40% |
| Q4 2019 Q2Q % growth | -0.56 | -0.59 | 0.03 | 4.93% |
| Q3 2019 Q2Q % growth | -0.48 | -0.57 | 0.09 | 16.41% |
| Q2 2019 Q2Q % growth | -0.61 | -0.47 | -0.14 | -29.61% |
| Q1 2019 Q2Q % growth | -0.41 | -0.41 | 0.00 | 0.34% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 6.599M | -6.599M | -100.00% | |
| Q1 2025 Q2Q % growth | 1.067M | -1.067M | -100.00% | |
| Q4 2024 Q2Q % growth | 10.914M | -10.914M | -100.00% | |
| Q3 2024 Q2Q % growth | -100.00% | 9.18M | -9.18M | -100.00% |
| Q2 2024 Q2Q % growth | -100.00% | 15.803M | -15.803M | -100.00% |
| Q1 2024 Q2Q % growth | -100.00% | 14.304M | -14.304M | -100.00% |
| Q4 2023 Q2Q % growth | -100.00% | 8.532M | -8.532M | -100.00% |
| Q3 2023 Q2Q % growth | 1.267M -64.81% | 11.404M | -10.137M | -88.89% |
| Q2 2023 Q2Q % growth | 294.123M 460.23% | 13.727M | 280.396M | 2,042.66% |
| Q1 2023 Q2Q % growth | 35.141M -16.53% | 29.294M | 5.847M | 19.96% |
| Q4 2022 Q2Q % growth | 10.3M -17.60% | 13.378M | -3.078M | -23.01% |
| Q3 2022 Q2Q % growth | 3.6M -32.08% | 14.762M | -11.162M | -75.61% |
| Q2 2022 Q2Q % growth | 52.5M 129.26% | 44.779M | 7.721M | 17.24% |
| Q1 2022 Q2Q % growth | 42.1M 432.91% | 26.206M | 15.894M | 60.65% |
| Q4 2021 Q2Q % growth | 12.5M -96.05% | 45.721M | -33.221M | -72.66% |
| Q3 2021 Q2Q % growth | 5.3M -43.62% | 30.887M | -25.587M | -82.84% |
| Q2 2021 Q2Q % growth | 22.9M 294.83% | 28.474M | -5.574M | -19.58% |
| Q1 2021 Q2Q % growth | 7.9M 119.44% | 32.256M | -24.356M | -75.51% |
| Q4 2020 Q2Q % growth | 316.8M 6,640.43% | 79.773M | 237.027M | 297.13% |
| Q3 2020 Q2Q % growth | 9.4M -30.88% | 384.98M | -375.58M | -97.56% |
| Q2 2020 Q2Q % growth | 5.8M 38.10% | 3.859M | 1.941M | 50.30% |
| Q1 2020 Q2Q % growth | 3.6M -14.29% | 5.107M | -1.507M | -29.51% |
| Q4 2019 Q2Q % growth | 4.7M | 8.791M | -4.091M | -46.54% |
| Q3 2019 Q2Q % growth | 13.6M | 9.514M | 4.086M | 42.95% |
| Q2 2019 Q2Q % growth | 4.2M | 3.999M | 201K | 5.03% |
| Q1 2019 Q2Q % growth | 4.2M | 9.301M | -5.101M | -54.84% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -1.08% |
| Revenue | 0% | 0% | 0% | -27.96% |